Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects

NCT07445815 is registered in ClinicalTrials.gov with Lanzhou Institute of Biological Products Co., Ltd as lead sponsor.

NCT NCT07445815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07445815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
Lead sponsor
Lanzhou Institute of Biological Products Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
August 21, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rabies (healthy volunteers)